An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

PHASE3RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

March 27, 2026

Study Completion Date

March 27, 2026

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Sonelokimab

Open label

Trial Locations (17)

20010

RECRUITING

Clinical Site, Washington D.C.

23502

RECRUITING

Clinical Site, Norfolk

29425

RECRUITING

Clinical Site, Charleston

30328

RECRUITING

Clinical Site, Sandy Springs

31217

RECRUITING

Clinical Site, Macon

33021

RECRUITING

Clinical Site, Hollywood

33136

RECRUITING

Clinical Site, Miami

42071

RECRUITING

Clinical Site, Murray

47201

RECRUITING

Clinical Site, Columbus

48328

RECRUITING

Clinical Site, Waterford

58103

RECRUITING

Clinical Site, Fargo

60611

RECRUITING

Clinical Site, Chicago

72117

RECRUITING

Clinical Site, North Little Rock

75025

RECRUITING

Clinical Site, Plano

78218

RECRUITING

Clinical Site, San Antonio

94304

RECRUITING

Clinical Site, Stanford

75390-8575

RECRUITING

Clinical Site, Dallas

Sponsors
All Listed Sponsors
lead

MoonLake Immunotherapeutics AG

INDUSTRY

NCT06768671 - An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) | Biotech Hunter | Biotech Hunter